• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

90-kDa热休克蛋白抑制通过消耗Chk1和Wee1消除了拓扑异构酶I毒物诱导的p53基因缺失肿瘤细胞中的G2/M期检查点。

90-kDa heat shock protein inhibition abrogates the topoisomerase I poison-induced G2/M checkpoint in p53-null tumor cells by depleting Chk1 and Wee1.

作者信息

Tse Archie N, Sheikh Tahir N, Alan Ho, Chou Ting-Chao, Schwartz Gary K

机构信息

Laboratory of New Drug Development, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.

出版信息

Mol Pharmacol. 2009 Jan;75(1):124-33. doi: 10.1124/mol.108.050807. Epub 2008 Sep 26.

DOI:10.1124/mol.108.050807
PMID:18820127
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2685054/
Abstract

The G(2)/M cell cycle checkpoint is regulated by a multitude of signaling pathways after genotoxic stress. Herein, we report that treatment with the 90-kDa heat shock protein (Hsp90) molecular chaperone inhibitor 17-allylamino-17-demethoxygeldanamycin (17AAG) selectively abrogates the G(2)/M checkpoint induced by 7-ethyl-10-hydroxycamptothecin (SN-38), an active metabolite of irinotecan, in p53-null compared with p53-intact HCT116 colon cancer cells. The basis for this selectivity can be explained in part by the lack of p21 induction in p53-null cells. In accord with published results, we could show that treatment with 17AAG resulted in depletion of Chk1, a known Hsp90 client protein. In addition, we observed a time- and dose-dependent decrease in Wee1 kinase level, a negative regulator of mitosis, after 17AAG treatment in gastrointestinal cancer cells. Depletion of Wee1 protein preceded mitotic entry induced by 17AAG, and this decrease could be partially rescued by cotreatment with a proteasome inhibitor. Coimmunoprecipitation experiments showed that Hsp90 and Wee1 interacted in whole cells, and 17AAG treatment decreased the degradative half-life of Wee1, indicating that Wee1 is another Hsp90 client in mammalian cells. Knockdown of Chk1 and Wee1 by short interfering RNA each resulted in abrogation of the G(2)/M checkpoint induced by SN-38. The combination of SN-38 and 17AAG was shown to be synergistic in p53-null but not in parental HCT116 cells by median effect/combination index analysis. Taken together, 17AAG specifically inhibits the G(2)/M checkpoint in p53-defective cells by down-regulation of two critical checkpoint kinases, Chk1 and Wee1.

摘要

基因毒性应激后,G(2)/M细胞周期检查点受多种信号通路调控。在此,我们报告,与p53完整的HCT116结肠癌细胞相比,用90-kDa热休克蛋白(Hsp90)分子伴侣抑制剂17-烯丙基氨基-17-去甲氧基格尔德霉素(17AAG)处理可选择性消除由伊立替康的活性代谢物7-乙基-10-羟基喜树碱(SN-38)诱导的p53缺失细胞中的G(2)/M检查点。这种选择性的基础部分可通过p53缺失细胞中缺乏p21诱导来解释。与已发表的结果一致,我们可以证明用17AAG处理会导致已知的Hsp90客户蛋白Chk1的消耗。此外,我们观察到在胃肠道癌细胞中用17AAG处理后,有丝分裂的负调节因子Wee1激酶水平呈时间和剂量依赖性下降。在17AAG诱导有丝分裂进入之前,Wee1蛋白就已耗尽,并且这种下降可通过与蛋白酶体抑制剂共同处理而部分挽救。免疫共沉淀实验表明,Hsp90和Wee1在全细胞中相互作用,17AAG处理降低了Wee1的降解半衰期,表明Wee1是哺乳动物细胞中的另一种Hsp90客户蛋白。通过短干扰RNA敲低Chk1和Wee1均导致SN-38诱导的G(2)/M检查点被消除。通过中位效应/联合指数分析表明,SN-38和17AAG的组合在p53缺失细胞中具有协同作用,但在亲本HCT116细胞中则不然。综上所述,17AAG通过下调两种关键的检查点激酶Chk1和Wee1,特异性抑制p53缺陷细胞中的G(2)/M检查点。

相似文献

1
90-kDa heat shock protein inhibition abrogates the topoisomerase I poison-induced G2/M checkpoint in p53-null tumor cells by depleting Chk1 and Wee1.90-kDa热休克蛋白抑制通过消耗Chk1和Wee1消除了拓扑异构酶I毒物诱导的p53基因缺失肿瘤细胞中的G2/M期检查点。
Mol Pharmacol. 2009 Jan;75(1):124-33. doi: 10.1124/mol.108.050807. Epub 2008 Sep 26.
2
Chk1 and Wee1 control genotoxic-stress induced G2-M arrest in melanoma cells.Chk1和Wee1调控黑色素瘤细胞中基因毒性应激诱导的G2-M期阻滞。
Cell Signal. 2015 May;27(5):951-60. doi: 10.1016/j.cellsig.2015.01.020. Epub 2015 Feb 12.
3
Geldanamycin promotes premature mitotic entry and micronucleation in irradiated p53/p21 deficient colon carcinoma cells.格尔德霉素促进照射后 p53/p21 缺陷结肠癌细胞过早进入有丝分裂和微核形成。
Oncogene. 2008 Sep 18;27(42):5567-77. doi: 10.1038/onc.2008.172. Epub 2008 May 26.
4
A phase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors.伊立替康联合17-烯丙基氨基-17-去甲氧基格尔德霉素用于实体瘤患者的1期剂量递增研究。
Clin Cancer Res. 2008 Oct 15;14(20):6704-11. doi: 10.1158/1078-0432.CCR-08-1006.
5
Blockade of Hsp90 by 17AAG antagonizes MDMX and synergizes with Nutlin to induce p53-mediated apoptosis in solid tumors.17AAG 通过阻断 Hsp90 拮抗 MDMX 并与 Nutlin 协同作用诱导实体瘤中 p53 介导的细胞凋亡。
Cell Death Dis. 2011 May 12;2(5):e156. doi: 10.1038/cddis.2011.39.
6
Hsp90 inhibitors sensitise human colon cancer cells to topoisomerase I poisons by depletion of key anti-apoptotic and cell cycle checkpoint proteins.Hsp90 抑制剂通过耗竭关键的抗凋亡和细胞周期检查点蛋白使人类结肠癌细胞对拓扑异构酶 I 毒物敏感。
Biochem Pharmacol. 2012 Feb 1;83(3):355-67. doi: 10.1016/j.bcp.2011.11.017. Epub 2011 Nov 28.
7
p53 independent radio-sensitization of human lymphoblastoid cell lines by Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin.Hsp90 抑制剂 17-allylamino-17-demethoxygeldanamycin 对人淋巴母细胞系的 p53 非依赖性放射增敏作用。
Oncol Rep. 2010 Jan;23(1):199-203.
8
The role of checkpoint kinase 1 in sensitivity to topoisomerase I poisons.检查点激酶1在对拓扑异构酶I抑制剂敏感性中的作用。
J Biol Chem. 2005 Apr 8;280(14):14349-55. doi: 10.1074/jbc.M411890200. Epub 2005 Feb 7.
9
Hsp90-inhibitor geldanamycin abrogates G2 arrest in p53-negative leukemia cell lines through the depletion of Chk1.热休克蛋白90抑制剂格尔德霉素通过消耗Chk1消除p53阴性白血病细胞系中的G2期阻滞。
Oncogene. 2008 May 15;27(22):3091-101. doi: 10.1038/sj.onc.1210978. Epub 2007 Dec 10.
10
Hsp90 inhibitor-mediated disruption of chaperone association of ATR with hsp90 sensitizes cancer cells to DNA damage.热休克蛋白 90 抑制剂介导的 ATR 与热休克蛋白 90 伴侣复合物的解离使癌细胞对 DNA 损伤敏感。
Mol Cancer Ther. 2011 Jul;10(7):1194-206. doi: 10.1158/1535-7163.MCT-11-0094. Epub 2011 May 12.

引用本文的文献

1
Effects of Radiotherapy in Combination With Irinotecan and 17-AAG on Bcl-2 and Caspase 3 Gene Expression in Colorectal Cancer Cells.放疗联合伊立替康和17-AAG对大肠癌细胞中Bcl-2和Caspase 3基因表达的影响
J Lasers Med Sci. 2022 Feb 28;13:e9. doi: 10.34172/jlms.2022.09. eCollection 2022.
2
PKMYT1 as a Potential Target to Improve the Radiosensitivity of Lung Adenocarcinoma.PKMYT1作为提高肺腺癌放射敏感性的潜在靶点。
Front Genet. 2020 Apr 29;11:376. doi: 10.3389/fgene.2020.00376. eCollection 2020.
3
DAF-21/Hsp90 is required for C. elegans longevity by ensuring DAF-16/FOXO isoform A function.DAF-21/Hsp90 通过确保 DAF-16/FOXO 同工型 A 的功能来维持线虫的寿命。
Sci Rep. 2018 Aug 13;8(1):12048. doi: 10.1038/s41598-018-30592-6.
4
Regulation of G2/M Transition by Inhibition of WEE1 and PKMYT1 Kinases.抑制 WEE1 和 PKMYT1 激酶对 G2/M 期转换的调控。
Molecules. 2017 Nov 23;22(12):2045. doi: 10.3390/molecules22122045.
5
Re-examining HSPC1 inhibitors.重新审视HSPC1抑制剂。
Cell Stress Chaperones. 2017 Mar;22(2):293-306. doi: 10.1007/s12192-017-0774-0. Epub 2017 Mar 2.
6
Rational Combinations of Targeted Agents in AML.急性髓系白血病中靶向药物的合理联合应用
J Clin Med. 2015 Apr 10;4(4):634-664. doi: 10.3390/jcm4040634. eCollection 2015 Apr.
7
Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights.组蛋白去乙酰化酶抑制剂(HDACI)的作用机制:新见解
Pharmacol Ther. 2014 Sep;143(3):323-36. doi: 10.1016/j.pharmthera.2014.04.004. Epub 2014 Apr 24.
8
Molecular targets and mechanisms of radiosensitization using DNA damage response pathways.利用 DNA 损伤反应通路实现放射增敏的分子靶点和机制。
Future Oncol. 2013 Feb;9(2):219-33. doi: 10.2217/fon.12.185.
9
Non-specific chemical inhibition of the Fanconi anemia pathway sensitizes cancer cells to cisplatin.非特异性化学抑制范可尼贫血途径可使癌细胞对顺铂敏感。
Mol Cancer. 2012 Apr 26;11:26. doi: 10.1186/1476-4598-11-26.
10
Cooperative enhancement of radiosensitivity after combined treatment of 17-(allylamino)-17-demethoxygeldanamycin and celecoxib in human lung and colon cancer cell lines.17-(烯丙氨基)-17-去甲氧基格尔德霉素与塞来昔布联合应用对人肺癌和结肠癌细胞系放射增敏作用的协同增强。
DNA Cell Biol. 2012 Jan;31(1):15-29. doi: 10.1089/dna.2011.1342. Epub 2011 Aug 10.

本文引用的文献

1
Geldanamycin promotes premature mitotic entry and micronucleation in irradiated p53/p21 deficient colon carcinoma cells.格尔德霉素促进照射后 p53/p21 缺陷结肠癌细胞过早进入有丝分裂和微核形成。
Oncogene. 2008 Sep 18;27(42):5567-77. doi: 10.1038/onc.2008.172. Epub 2008 May 26.
2
Differential roles for checkpoint kinases in DNA damage-dependent degradation of the Cdc25A protein phosphatase.关卡激酶在DNA损伤依赖性Cdc25A蛋白磷酸酶降解中的不同作用。
J Biol Chem. 2008 Jul 11;283(28):19322-8. doi: 10.1074/jbc.M802474200. Epub 2008 May 13.
3
DNA damage-induced S phase arrest in human breast cancer depends on Chk1, but G2 arrest can occur independently of Chk1, Chk2 or MAPKAPK2.DNA损伤诱导的人乳腺癌S期阻滞依赖于Chk1,但G2期阻滞可独立于Chk1、Chk2或MAPKAPK2发生。
Cell Cycle. 2008 Jun 1;7(11):1668-77. doi: 10.4161/cc.7.11.5982. Epub 2008 Mar 23.
4
Hsp90-inhibitor geldanamycin abrogates G2 arrest in p53-negative leukemia cell lines through the depletion of Chk1.热休克蛋白90抑制剂格尔德霉素通过消耗Chk1消除p53阴性白血病细胞系中的G2期阻滞。
Oncogene. 2008 May 15;27(22):3091-101. doi: 10.1038/sj.onc.1210978. Epub 2007 Dec 10.
5
Targeting checkpoint kinase 1 in cancer therapeutics.在癌症治疗中靶向检查点激酶1。
Clin Cancer Res. 2007 Apr 1;13(7):1955-60. doi: 10.1158/1078-0432.CCR-06-2793.
6
p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage.p53基因缺陷型细胞在DNA损伤后依靠通过p38丝裂原活化蛋白激酶/ MAPK活化蛋白激酶2途径的ATM和ATR介导的检查点信号传导来存活。
Cancer Cell. 2007 Feb;11(2):175-89. doi: 10.1016/j.ccr.2006.11.024.
7
CHIR-124, a novel potent inhibitor of Chk1, potentiates the cytotoxicity of topoisomerase I poisons in vitro and in vivo.CHIR-124是一种新型的强效Chk1抑制剂,在体外和体内均可增强拓扑异构酶I抑制剂的细胞毒性。
Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):591-602. doi: 10.1158/1078-0432.CCR-06-1424.
8
Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies.药物联合研究中协同作用和拮抗作用的理论基础、实验设计及计算机模拟
Pharmacol Rev. 2006 Sep;58(3):621-81. doi: 10.1124/pr.58.3.10.
9
Hsp90: a novel target for cancer therapy.热休克蛋白90:癌症治疗的新靶点。
Curr Top Med Chem. 2006;6(11):1205-14. doi: 10.2174/156802606777812068.
10
Chaperoning steroid hormone action.陪伴甾体激素作用
Trends Endocrinol Metab. 2006 Aug;17(6):229-35. doi: 10.1016/j.tem.2006.06.003. Epub 2006 Jun 27.